Thrifty Banker
  • Politics
  • Business
  • World
  • Investing
  • Politics
  • Business
  • World
  • Investing

Thrifty Banker

Business

Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic

by June 26, 2024
June 26, 2024
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic

Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. 

Demand for Wegovy and Ozempic has outstripped supply over the last year, spurring intermittent shortages in the U.S. and forcing the Danish drugmaker to invest heavily to increase its manufacturing footprint. The company said it plans to invest $6.8 billion in production this year, up from roughly $4 billion last year. 

The new manufacturing facility will be responsible for filling and packaging syringes and injection pens for the drugs, according to a company release. 

An Ozempic injection pen.David J. Phillip / AP

“This investment really gives us the opportunity to serve more patients,” Doug Langa, Novo Nordisk’s head of North American operations, said in an interview. “Importantly, I think the other key message here is it’s further investment in the U.S., so I think we’re very proud of that.”

Construction of the 1.4 million-square-foot facility has begun and is expected to be completed between 2027 and 2029, Novo Nordisk said. The company said 1,000 workers will staff the site, adding to the 2,500 employees already working at its three existing manufacturing plants in North Carolina. 

That includes two sites that are already operational in Clayton — one responsible for fill and finish work and another dedicated to producing the active ingredient in the company’s diabetes pill Rybelsus. The company also has a site in Durham, North Carolina, responsible for manufacturing and packaging oral drugs and another facility in West Lebanon, New Hampshire.

Twelve other production sites are located in Denmark, France, China, Japan, Algeria, Brazil, Iran and Russia, according to a Novo Nordisk spokesperson.

Three lower doses of Wegovy are currently in shortage in the U.S. due to high demand, according to a Food and Drug Administration database. Patients start Wegovy with lower doses and gradually increase the amount every four weeks until they reach a target dosage.

Wegovy is an injectable prescription weight loss medicine. Michael Siluk / Universal Images Group via Getty Images

Wegovy and Ozempic are part of a class of medications called GLP-1s that mimic hormones produced in the gut to suppress a person’s appetite and regulate their blood sugar.

Around 35,000 U.S. patients on average start Wegovy each week today, up from roughly 27,000 in May, a Novo Nordisk spokesperson said in a statement. Still, Langa said the company is being “very purposeful” about how many lower doses it is releasing into the U.S. market to ensure patients who have already started taking Wegovy can continue treatment with higher doses.

Rival drugmaker Eli Lilly has also committed billions of dollars to increase manufacturing capacity for its popular GLP-1s for weight loss and diabetes, Zepbound and Mounjaro. The company similarly has several production plants in North Carolina. 

This post appeared first on NBC NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
How Delta made itself America’s luxury airline — and what United wants to do about it
next post
Hooters to close ‘underperforming’ restaurants amid broader industry woes

Related Posts

Housing market may be thawing as rates dip...

December 13, 2023

Paramount and Skydance inch closer to a merger...

April 30, 2024

Netflix stock is trading at all-time high levels...

May 4, 2025

Consumer advocates, realtors hail NAR settlement: What it means...

March 25, 2024

Biden administration to lower costs for 64 drugs...

June 28, 2024

Laid-off tech workers turn to LinkedIn, therapy and...

March 13, 2024

McDonald’s plans to eliminate self-service soda stations at...

September 13, 2023

Apple boosts U.S. investment plans with $500 billion...

February 25, 2025

Comcast to bundle Peacock, Netflix and Apple TV+...

May 15, 2024

YouTube is dominating the living room, forcing media...

June 28, 2024

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular

    • 1

      Top 10 Countries for Natural Gas Production (Updated 2024)

      April 6, 2024
    • 2

      Understanding Lithium Mineralogy from an Investment Perspective

      September 12, 2023
    • 3

      US Capital Global Facilitates $50MM Financing to Accelerate Charbone Hydrogen’s North American Expansion

      June 6, 2025
    • 4

      Israel confirms it is arming Hamas rivals in operation opposition calls ‘complete madness’

      June 6, 2025
    • 5

      A GOP operative accused a monastery of voter fraud. Nuns fought back.

      January 3, 2025
    • 6

      Crypto Market Recap: Strategy Eyes US$1B Raise for Bitcoin Push, UK Regulator Reverses ETN Ban

      June 6, 2025
    • 7

      China’s aircraft carriers send message in the open Pacific for the first time – and bigger and more powerful ships are coming

      June 16, 2025

    Categories

    • Business (1,053)
    • Investing (2,079)
    • Politics (2,977)
    • Uncategorized (20)
    • World (3,387)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: thriftybanker.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thriftybanker.com | All Rights Reserved